The lipid phosphatase‐like protein PLPPR1 associates with RhoGDI1 to modulate RhoA activation in response to axon growth inhibitory molecules

Abstract

Phospholipid Phosphatase-Related Protein Type 1 (PLPPR1) is a member of a family of lipid phosphatase related proteins, integral membrane proteins characterized by six transmembrane domains. This family of proteins is enriched in the brain and recent data indicate potential pleiotropic functions in several different contexts. An inherent ability of this family of proteins is to induce morphological changes, and we have previously reported that members of this family interact with each other and may function co-operatively. However, the function of PLPPR1 is not yet understood.Here we show that the expression of PLPPR1 reduces the inhibition of neurite outgrowth of cultured mouse hippocampal neurons by chondroitin sulfate proteoglycans and the retraction of neurites of Neuro-2a cells by lysophosphatidic acid (LPA).Further, we show that PLPPR1 reduces the activation of Ras homolog family member A (RhoA) by LPA in Neuro-2a cells, and that this is because of an association of PLPPR1with the Rho-specific guanine nucleotide dissociation inhibitor (RhoGDI1).These results establish a novel signaling pathway for the PLPPR1 protein.

Cell type-specific gene expression dynamics during human brain maturation

“…5c). PLPPR1 is higher in the postnatal mouse hippocampus than in the adult 56 and is also known to regulate axon growth by modulating cytoskeletal dynamics 57 . In Inh_L2-6_VIP_QPCT, a single lncRNA, LINC00276, was upregulated (Fig.…”

Editorial: Exciting developments in neurochemistry research and publishing

“…We are excited to see the quality and diversity of the work submitted and accepted for publication by the Journal of Neurochemistry . From molecular mechanisms in cultured cells (Agbaegbu Iweka et al, 2021; Bendahmane et al, 2020), neurochemical mechanisms in intact organisms (Abreu et al, 2021; Becker et al, 2021), new imaging and quantitative methodologies providing insight into neurochemical changes (Abdalla et al, 2020; Arber et al, 2021; Blank & Hopf, 2021; Dienel, 2021) and critical biomarkers in disease (Altmayer et al, 2021; Chakraborty & Basu, 2021; Chatterjee et al, 2021; Eden et al, 2021; Geula et al, 2021; Ginsberg et al, 2021; Glezer et al, 2021), the scope of the Journal of Neurochemistry has broadened to respond to the demands of our scientific community. Neurochemical mechanisms of disease are a popular topic covering neuropsychiatric and developmental disorders (Haase et al, 2021; Kozlowska et al, 2021; Liu & McNally, 2021; Nie et al, 2021; Nomura et al, 2021) and neurodegenerative diseases (Brosseron et al, 2021; Butler et al, 2021; Chatterjee et al, 2021; Korecka & Shaw, 2021; Sathe et al, 2021; Trinh et al, 2021; Yuede et al, 2021).…”